title: Masterful Antibodies: Checkpoint Blockade.
abstract: Cancer therapeutics that target the immune system rather than the cancer cell itself are becoming standard of care in a growing number of different malignancies. Although cancer immunotherapy is not a new concept, the potential importance of this class of drugs was probably not fully appreciated as recently as a decade ago when much of the focus of cancer drug discovery was on cancer cell-targeted medicines. The authors were lucky enough to be able to witness and participate in the discovery and development of ipilimumab and nivolumab, two relatively early examples of immune system-targeted drugs. The challenges associated with discovering and developing these molecules may be of historical interest and instructive for moving cancer immunotherapy forward for greater numbers of patients.Cancer Immunol Res; 5(4); 275-81. ©2017 AACR.
authors.affiliation: Bristol-Myers Squibb, Biologics Discovery California, Redwood City, California. nils.lonberg@bms.com.
authors.forename: Nils
authors.initials: N
authors.lastname: Lonberg
authors.affiliation: Bristol-Myers Squibb, Biologics Discovery California, Redwood City, California.
authors.forename: Alan J
authors.initials: AJ
authors.lastname: Korman
mesh_terms: D000074322:Antineoplastic Agents, Immunological / Q000494:pharmacology* / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors / Q000276:immunology; D003131:Combined Modality Therapy; D055808:Drug Discovery; D006801:Humans; D056747:Immunomodulation / Q000187:drug effects*; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism / Q000401:mortality; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000074322:Antineoplastic Agents, Immunological; D060890:B7-H1 Antigen; D014408:Biomarkers, Tumor; D060908:CTLA-4 Antigen; D061026:Programmed Cell Death 1 Receptor